Zynerba Pharmaceuticals, Inc ZYNE

meitshel Premium

This is not a financial advice! Most info on the chart. Trade carefully!

MarketMoversReport

ZYNE: Zynerba Pharmaceuticals, Inc. 2022-06-22 20:05:00 Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

fract Premium

Legalization impact on Zynerba stock can be tracked in this TA. Local psychological levels are the fibonacci intersections nearest to the price. Accordingly the long-term targets are also guided with same system. Move cursor over intersections to see those price levels. See if they coincide with your targets.

opiumfive Pro Updated 

ZYNE is near 2 good support trendlines, also some good big volumes were entering past 2 days.

fract Premium

When it comes to pullbacks Zynerba is doing well there, especially it becomes more considerable when we see that price is getting close and close to all time lows. Buying now is ok but a little riskier than buying when price touches or enters down inside green area and touches closest fib line. A movement from current price to $4 is 40% increase and we know the...

neriokas22

Just saving this for myself to look back at later lulz. But yeah I think it's decision time. I think chances are it spikes soon and good targets could be those yellow circles, but there's a chance we keep bleeding so not financial advice, educational for myself ;)

AlexanderFD

I would like to represent my idea on the traiding view. Here we can see a little pullback from the bottom and looks like the trend has changed for a while. I'm waiting the ZYNE 1) 5.00$ Price 2) 5.95$ 2Price

Glamych

№2

Glamych

Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel

NaikoN81

The price is approaching the support level of $ 4.10 and will test it. 1. If it rebounds, it will most likely go up to the resistance level of $ 4.85 and test it. (+ 20% growth). 2. If the price breaks through the support level, it will rush to the global support level of $ 3.31 (fall by 22%) and most likely rebound from it and go up. If you like the idea, do not...

fract Premium

Too much speculative capital pushing the price back and forth. At this point of time I'd wait for the price to stabilize at decent range first. I will look for the decline in volatility into triangular pattern formation. It's important for the market to shake off short-term bears to clarify the level at which long-term bulls are willing to hold the price before...

Options360 Premium Updated 

ZYNE is a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It has an extremely volatile chart. Trade carefully here. Do your own due diligence, your risk is 100% your responsibility. You win some or you learn some. Consider being charitable with some of your profit to help...

Vcollective Updated 

Divergence on Stoch and MACD. At support

K_K88 Premium

A huge triangle is ready to break out - the stock has been making higher-low, so we will see a higher high soon. Plus there is golden cross confirmation on daily chart

und_hectorhog

Want to see this maintain price at the .618 fib at $5.80 for a potential entry as it looks for a possible long term reversal as this was a $16 stock in 2019.

HKStocks89

ZYNERBA PHARMACEUTICALS INC NEXT MOVE

StairsTrades Premium

ZYNE lost its marbles along with the entire Cannabis sector. Here are the levels Im watching. Until then I am staying on the sidelines.

AlenCiken

Jazz Pharmaceuticals $JAZZ agreed to buy GW Pharmaceuticals $GWPH for $7.2 billion last wednesday sending shares of fellow epilepsy-focused biotech companies $ZYNE flying. "The acquisition allows Jazz to become a significant epilepsy player by adding Epidiolex, which exited 2020 with sales annualizing at about $576 million despite a challenging Covid environment...